By-Health: The scale of the funds raised has increased to 2.9 billion yuan.

Tianjin Pharmaceuticals announced that the company had previously invested 130 million yuan of its own funds in Lishi Xingling. Recently, Lishi Xingling has added limited partners, and the size of funds raised has increased from 680 million yuan to 2.9 billion yuan. The related fundraising work has been completed, and the funds have all been fully paid. The company's contribution as a limited partner and the method of contribution have not changed, and the main terms of the partnership agreement have not changed significantly. This development has no significant impact on the company.